Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
49 studies found for:    "Myasthenia gravis"
Show Display Options
Download search resultsDownload the search results for:
"Myasthenia gravis" (49 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Mycophenolate Mofetil in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: mycophenolate mofetil
2 Recruiting Exercise for Stable Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: Exercise
3 Completed
Has Results
Efficacy of Methotrexate in Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate;   Other: Placebo
4 Recruiting Tissue Repository for Studies of Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: No interventions
5 Active, not recruiting Phase II Trial of Rituximab In Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Rituximab;   Drug: Placebo
6 Terminated Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
7 Completed Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Intravenous ImmuneGlobulin
8 Recruiting Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Behavioral: Physical exercise programme using a rowing machine
9 Completed FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Condition: Myasthenia Gravis
Interventions: Drug: tacrolimus;   Drug: placebo
10 Active, not recruiting Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy;   Drug: prednisone
11 Active, not recruiting Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Prednisone - Azathioprine
12 Unknown  A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
13 Recruiting Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Biological: CV-MG01;   Biological: Placebo
14 Completed Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
Conditions: Myositis;   Myasthenia Gravis
Intervention: Drug: Rituximab
15 Completed A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Condition: Refractory Myasthenia Gravis
Intervention: Drug: Rituximab (Rituxan)
16 Completed Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Condition: Generalized Myasthenia Gravis
Interventions: Biological: GB-0998 (Intravenous immunoglobulin);   Procedure: Plasmapheresis
17 Recruiting Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Condition: Myasthenia Gravis, Generalized
Interventions: Drug: Placebo;   Drug: CFZ533
18 Completed Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Condition: Refractory Generalized Myasthenia Gravis
Interventions: Biological: Eculizumab;   Drug: Placebo
19 Active, not recruiting ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Condition: Refractory Generalized Myasthenia Gravis
Intervention: Biological: Eculizumab
20 Terminated Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Subcutaneous immunoglobulins

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years